Glaucoma and Keratoprosthesis Surgery

Rivier, Delphine; Paula, Jayter Silva; Kim, Eva; Dohlman, Claes H.; Grosskreutz, Cynthia L.

doi:10.1097/ijg.0b013e3181815485

Cited by 67 publications

(26 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progression of preexisting glaucoma after B-KPro implantation has been estimated to be as high as 25% [83] with the fastest rates of progression occurring in patients requiring keratoprosthesis for corneal burns, and the slowest in those with no history of prior corneal surgery [80▪]. Additionally, de novo glaucoma occurring after B-KPro has been reported to range from 2 to 28% [79,80▪,81,82,84, 85,89,90]. …”

Section: Glaucoma After Boston Keratoprosthesismentioning

confidence: 99%

See 1 more Smart Citation

Glaucoma management after corneal transplantation surgeries

Kornmann

Gedde

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of review Intraocular pressure (IOP) elevation and glaucoma progression following corneal transplantation, specifically, penetrating keratoplasty, Descemet’s stripping endothelial keratoplasty, and Boston keratoprosthesis, are well described causes of ocular morbidity. Depending on the procedure performed, the incidence of glaucoma is highly variable. Several etiologic factors have been identified, the most common being synechial angle closure and corticosteroid-induced IOP elevation. The purpose of this review is to describe the various treatment strategies for glaucoma following corneal transplantation. Recent findings Medications and laser treatments are usually first-line therapies for postoperative IOP elevation. Surgical intervention, including filtering surgery and glaucoma drainage devices, may be necessary to control IOP and prevent progressive glaucomatous damage. Summary Glaucoma is a common complication of corneal transplantation, and the degree of aggressiveness is often related to the indication for corneal surgery. Although postoperative IOP elevation may be controlled with medical therapy alone, refractory cases may require glaucoma surgery. In all cases, early detection and intervention are necessary to optimize patient outcomes.

show abstract

Section: Glaucoma After Boston Keratoprosthesismentioning

confidence: 99%

“…CPC can be performed at the time of, or subsequent to, B-KPro placement [84,89,97,98]. Rivier et al [89] reported the results of 18 eyes with B-KPro undergoing diode transscleral CPC, 13 of which were performed after previously implanted GDDs failed to adequately control IOP.…”

Section: Glaucoma After Boston Keratoprosthesismentioning

confidence: 99%

Glaucoma management after corneal transplantation surgeries

Kornmann

Gedde

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…32 In this series, complications included one case of conjunctival dehiscence and the other with fungal endophthalmitis. 32 …”

Section: Iv) Effective Medical and Laser Treatment For Glaucoma In Eymentioning

confidence: 93%

“…They found a significantly decreased IOP after laser without a significant change in final visual acuity, in 18 eyes during a mean follow-up of 26.6 months ±19.6 months. 32 Furthermore, 33.3% required additional laser and 11% required more than two sessions. 32 In this series, complications included one case of conjunctival dehiscence and the other with fungal endophthalmitis.…”

Section: Iv) Effective Medical and Laser Treatment For Glaucoma In Eymentioning

confidence: 99%

See 1 more Smart Citation

Innovative Approaches to Glaucoma Management of Boston Keratoprosthesis Type 1

Vajaranant

Liu

Cortina

et al. 2016

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Glaucoma remains a prevalent disorder and visual limiting factor after Boston keratoprosthesis type 1 implantation. Patients with glaucoma have worse initial and late visual acuity outcomes after otherwise successful keratoprosthesis implantation. Management of glaucoma in the setting of a keratoprosthesis is challenging because of relatively rapid progression and an inability to accurately measure intraocular pressure (IOP). In addition, there are no standard guidelines for glaucoma surveillance and monitoring after keratoprosthesis surgery. This report provides a review of the current literature and offers innovative strategies that will overcome the challenges in managing glaucoma in the setting of a Boston keratoprosthesis type 1 implant. The topics that will be discussed in this section include alternative methods for IOP measurement, rationales and surgical techniques for a pars plana tube placement for glaucoma drainage device, effective medical and laser treatment, the risk for IOP elevations after YAG laser, and practical guides to glaucoma surveillance and monitoring.

show abstract